March 19, 2018 / 11:16 AM / in 4 months

BRIEF-Eylea (Aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial

March 19 (Reuters) - Regeneron Pharmaceuticals Inc:

* EYLEA® (AFLIBERCEPT) INJECTION DEMONSTRATES POSITIVE TOPLINE RESULTS IN PHASE 3 NON-PROLIFERATIVE DIABETIC RETINOPATHY TRIAL

* REGENERON PHARMA-PHASE 3 TRIAL EVALUATING EYLEA INJECTION IN MODERATELY SEVERE TO SEVERE NON-PROLIFERATIVE DIABETIC RETINOPATHY MET PRIMARY ENDPOINT

* REGENERON PHARMA - 58 PERCENT OF EYLEA-TREATED PATIENTS EXPERIENCED TWO-STEP OR GREATER IMPROVEMENT FROM BASELINE ON DIABETIC RETINOPATHY SEVERITY SCALE (DRSS) AT WEEK 24

* REGENERON PHARMACEUTICALS INC - THERE WAS ONE CASE OF MILD INTRAOCULAR INFLAMMATION (IOI) IN A PATIENT TREATED WITH EYLEA IN TRIAL

* REGENERON PHARMACEUTICALS - EXPECT U.S. REGULATORY SUBMISSION FOR DIABETIC RETINOPATHY LATER THIS YEAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below